BCRX

Biocryst Pharmaceuticals Inc

• TipRanks·05/20 02:07

  BioCryst Insider Makes a Six-Figure Move That Investors Can’t Ignore

• TipRanks·05/20 00:58

  BioCryst Earnings Call: ORLADEYO Momentum vs. Risks

• PUBT·05/19 20:08

  BioCryst director Amy E. McKee sells 11,180 shares worth $100,284.6

• Simply Wall St·05/16 14:32

  European Navenibart Deal And Reaffirmed 2026 Outlook Could Be A Game Changer For BioCryst (BCRX)

• PUBT·05/15 20:14

  BioCryst Chief Legal Officer Alane P. Barnes sells 62,500 shares for $596,250

• Simply Wall St·05/14 13:40

  BioCryst’s Navenibart Deal And Pediatric Data Shape HAE Investment Case

• Benzinga·05/13 11:15

  BioCryst Pharmaceuticals To Present New Real-World Evidence At The International Society For Pharmacoeconomics And Outcomes Research Conference, May 17–20

• Simply Wall St·05/09 19:40

  Is BioCryst Pharmaceuticals (BCRX) Pricing Reflect Its Pipeline Progress And Recent Share Performance Changes

• TipRanks·05/08 01:49

  RBC Capital Sticks to Their Buy Rating for BioCryst (BCRX)

• Benzinga·05/07 17:46

  These Analysts Revise Their Forecasts On BioCryst Pharma After Q1 Earnings

• Dow Jones·05/07 16:40

  BioCryst Pharmaceuticals Price Target Raised to $28.00/Share From $25.00 by Citizens

• Dow Jones·05/07 16:40

  BioCryst Pharmaceuticals Is Maintained at Market Outperform by Citizens

• Benzinga·05/07 16:30

  Citizens Maintains Market Outperform on BioCryst Pharma, Raises Price Target to $28

• Seeking Alpha·05/07 15:08

  Best Small Cap Value Stocks May 2026

• Dow Jones·05/07 14:47

  BioCryst Pharmaceuticals Price Target Cut to $21.00/Share From $22.00 by Wedbush